Synapse - Robert Motzer

Results (1252)

Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma

Journal Article

Motzer, R. J.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Alekseev, B. Y.; Lee, J. L.; Suarez, C.; Stroyakovskiy, D.; De Giorgi, U.; more...
JAMA Oncology (2022)

Fulltext@MSK | Save

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Journal Article

Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
Cell (2022)

Fulltext@MSK | Save

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: An open-label, randomised, phase 3 trial

Journal Article

Cella, D.; Motzer, R. J.; Suarez, C.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J. F.; Simsek, B.; Zhang, J.; Ivanescu, C.; more...
Lancet Oncology (2022)

Fulltext@MSK | Save

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: A sub-analysis of the METEOR study

Journal Article

Schmidinger, M.; Motzer, R. J.; Rolland, F.; Staehler, M.; Rink, M.; Retz, M.; Csoszi, T.; McCaffrey, J. A.; De Giorgi, U.; Caserta, C.; more...
Acta Oncologica (2022)

Fulltext@MSK | Save

Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Guidelines

Motzer, R. J.; Jonasch, E.; Agarwal, N.; Alva, A.; Baine, M.; Beckermann, K.; Carlo, M. I.; Choueiri, T. K.; Costello, B. A.; Derweesh, I. H.; more...
Journal of the National Comprehensive Cancer Network (2022)

Fulltext@MSK | Save

Changes, challenges and opportunities in cancer care during the COVID-19 era and beyond: Building on lessons learned from the pandemic

Review

Motzer, R. J.; Jonasch, E. A.; McGregor, B. A.; Figlin, R. A.
Kidney Cancer Journal (2021)

Fulltext@MSK | Save

Сохраненное время качественной жизни, проведенное без клинических симптомов и проявлений токсичности (Q-TWiST), при лечении комбинацией ленватиниба и эверолимуса по сравнению с монотерапией эверолимусом у пациентов с распространенным почечно-клеточным раком

Journal Article

Lee, C. H.; Wan, Y.; Smith, A.; Xie, R.; Motzer, R. J.
Onkourologiya (2021)

Fulltext@MSK | Save

Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms

Meeting Abstract

Grünwald, V.; Hutson, T.; Choueiri, T. K.; Motzer, R.; Rha, S. Y.; Alyasova, A.; Merchan, J.; Gurney, H.; Peer, A.; Takagi, T.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms

Meeting Abstract

Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso, G. T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial

Meeting Abstract

Bedke, J.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save